Pirfenex: Slows Idiopathic Pulmonary Fibrosis Progression
| Product dosage: 200 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $1.28 | $115.47 (0%) | 🛒 Add to cart |
| 180 | $1.01 | $230.93 $181.73 (21%) | 🛒 Add to cart |
| 270 | $0.84 | $346.40 $226.92 (34%) | 🛒 Add to cart |
| 360 | $0.78
Best per pill | $461.86 $281.14 (39%) | 🛒 Add to cart |
Pirfenex (pirfenidone) is an orally administered antifibrotic agent specifically indicated for the treatment of idiopathic pulmonary fibrosis (IPF). It is a disease-modifying therapy that targets the underlying pathological mechanisms of IPF, a chronic, progressive, and ultimately fatal interstitial lung disease. By reducing the rate of decline in lung function, Pirfenex represents a cornerstone in the management of this condition, offering a clinically proven intervention to alter its natural history. This medication requires careful patient selection and monitoring under the supervision of a pulmonologist or other specialist experienced in the treatment of IPF.
Features
- Active Pharmaceutical Ingredient: Pirfenidone
- Available Dosage Forms: Film-coated tablets (200 mg, 600 mg) and hard capsules (267 mg)
- Mechanism of Action: Multifunctional; exerts antifibrotic, anti-inflammatory, and antioxidant effects
- Primary Pharmacological Targets: Downregulates the production of transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α), key profibrotic cytokines
- Bioavailability: Well-absorbed orally, with high-fat meals significantly increasing exposure
- Metabolism: Primarily hepatic, via CYP1A2 and other enzymes, with extensive first-pass metabolism
- Elimination: Primarily renal (mostly as metabolites) with a half-life of approximately 2.5 hours
Benefits
- Slows Disease Progression: Demonstrated in clinical trials to significantly reduce the rate of decline in forced vital capacity (FVC), a key measure of lung function.
- Improves Progression-Free Survival: Extends the time to disease progression, defined as a categorical decline in FVC or death.
- Potential Mortality Benefit: Some studies and meta-analyses have shown a trend towards reduced all-cause mortality compared to placebo.
- Well-Characterized Safety Profile: The side effect profile is predictable and generally manageable with dose titration and supportive care.
- Oral Administration: Convenient tablet or capsule form allows for treatment outside of a clinical infusion setting.
Common use
Pirfenex is exclusively indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Its use is reserved for patients with a confirmed diagnosis of IPF, typically made by a multidisciplinary team including a pulmonologist, radiologist, and pathologist (where applicable) based on high-resolution computed tomography (HRCT) patterns and, in some cases, histology. It is not indicated for other interstitial lung diseases (ILDs), and its efficacy and safety in such conditions have not been established. Treatment is intended for long-term management to modify the disease course.
Dosage and direction
Dosage must be individualized and titrated to the full maintenance dose to improve tolerability.
- Initial Titration:
- Weeks 1-7: 267 mg (one capsule) three times daily (801 mg/day).
- Weeks 8-14: 534 mg (two capsules or one 600 mg tablet) three times daily (1602 mg/day).
- Maintenance Dose: 801 mg three times daily (2403 mg/day), taken with food to minimize nausea and dizziness.
- Administration: Tablets/capsules must be swallowed whole and should not be chewed, broken, or crushed. The three daily doses should be taken at approximately the same times each day (e.g., morning, afternoon, evening).
- Dosage Modification: Dose reduction or temporary interruption is required for management of certain adverse reactions (e.g., gastrointestinal symptoms, photosensitivity reaction, elevated liver enzymes). Please refer to the full prescribing information for specific guidance.
Precautions
- Photosensitivity and Phototoxicity: Pirfenex causes heightened skin sensitivity to sunlight (UVA/UVB) and artificial light sources (e.g., tanning beds). Severe sunburn and rashes can occur with minimal exposure.
- Precaution: Patients must use a high-SPF (≥50) broad-spectrum sunscreen and wear protective clothing (long sleeves, hats) when outdoors, even on cloudy days. Avoid direct sun exposure as much as possible.
- Liver Enzyme Elevations: ALT, AST, and bilirubin elevations have been observed. These are often asymptomatic but can be significant.
- Precaution: Liver function tests (ALT, AST, and bilirubin) must be conducted prior to initiation, monthly for the first 6 months, and then every 3 months thereafter thereafter.
- Gastrointestinal Disorders: Nausea, diarrhea, dyspepsia, vomiting, and gastroesophageal reflux disease are very common.
- Precaution: Taking doses with food is essential. Anti-emetics or proton pump inhibitors may be used prophylactically or therapeutically.
- Dizziness and Fatigue: These are common central nervous system-related adverse reactions.
- Precaution: Patients should be cautioned about operating machinery or driving until they know how Pirfenex affects them.
- Weight Loss: A significant proportion of patients experience decreased appetite and weight loss.
- Precaution: Patient weight should be monitored regularly. Nutritional support and dietary counseling may be necessary.
Contraindications
Pirfenex is contraindicated in patients with:
- Hypersensitivity to pirfenidone or any of the excipients in the formulation.
- Severe hepatic impairment (Child-Pugh Class C).
- Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease requiring dialysis.
- Concomitant use of strong CYP1A2 inhibitors (e.g., fluvoxamine, enoxacin). Use with moderate inhibitors (e.g., ciprofloxacin) requires close monitoring and potential dose reduction.
- A history of angioedema with pirfenidone use.
Possible side effect
The most common adverse reactions (incidence ≥10% and greater than placebo) are:
- Gastrointestinal: Nausea, diarrhea, dyspepsia, vomiting, abdominal pain, gastroesophageal reflux disease, decreased appetite.
- Dermatological: Rash, photosensitivity reaction, pruritus.
- General: Fatigue, asthenia, weight loss.
- Nervous System: Dizziness, headache.
- Respiratory: Upper respiratory tract infection.
- Hepatobiliary: Increased ALT, increased AST.
Serious but less common side effects include severe liver injury and angioedema.
Drug interaction
Pirfenidone is primarily metabolized by several CYP isozymes, including CYP1A2, making it susceptible to numerous interactions.
- Strong CYP1A2 Inhibitors (e.g., Fluvoxamine, Enoxacin): CONTRAINDICATED. Concomitant use significantly increases pirfenidone exposure and the risk of adverse effects.
- Moderate CYP1A2 Inhibitors (e.g., Ciprofloxacin): Use with caution. A dose reduction of Pirfenex is recommended during co-administrapy.
- CYP1A2 Inducers (e.g., Omeprazole, Smoking): May decrease pirfenidone exposure, potentially reducing efficacy. Smokers may require a higher dose, though smoking cessation during therapy will reverse this induction and necessitate a dose reduction to avoid toxicity. Concomitant use of omeprazole >20 mg daily is not recommended.
- Other Medicinal Products: Caution is advised with other drugs known to cause photosensitivity or hepatotoxicity.
Missed dose
If a dose is missed, it should be skipped and the next dose taken at the regularly scheduled time. Patients should not take a double dose to make up for a missed one. Maintaining the regular dosing schedule is more important than catching up on a single missed dose to avoid peak concentration-related side effects.
Overdose
There is no known specific antidote for pirfenidone overdose. Reported symptoms of overdose are extensions of its known adverse effects, including severe nausea, vomiting, dizziness, and photosensitivity reaction. Management involves immediate discontinuation of the drug, implementation of supportive and symptomatic care, including monitoring of vital signs and observation of the patient’s clinical status. Given the drug’s pharmacokinetics, dialysis is not expected to be effective due to high protein binding and extensive metabolism.
Storage
- Store below 30°C (86°F).
- Keep the bottle tightly closed in the original packaging to protect from moisture and light.
- Keep out of sight and reach of children.
Disclaimer
This information is for educational purposes and is not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The prescriber should be familiar with the full prescribing information before initiating therapy. The information herein is not exhaustive and may not include all data regarding uses, directions, warnings, precautions, interactions, or adverse effects.
Reviews
- “As a pulmonologist specializing in ILD, Pirfenex has been a practice-changing drug. While not a cure, the ability to demonstrably slow FVC decline gives us a tangible tool to offer our IPF patients. The side effects are real but manageable with a diligent titration schedule and proactive patient education, particularly regarding sun protection.” – Dr. A. Sharma, MD, Pulmonology.
- “The landmark ASCEND and CAPACITY trials provided the Level A evidence we needed. The ~50% reduction in the proportion of patients with a ≥10% decline in FVC or death is a statistically robust and clinically meaningful endpoint. It firmly established pirfenidone’s role as a first-line antifibrotic therapy.” – Clinical Researcher, Pharmaceutical Development.
- “The titration period was rough with the nausea, but taking it with a full meal made a world of difference. My scans have been stable for two years now, and my breathing hasn’t gotten worse. The sun sensitivity is no joke—I’ve become religious about sunscreen and hats.” – Patient with IPF, 68.